Free Trial

Syndax Pharmaceuticals (SNDX) SEC Filings & 10K Form

Syndax Pharmaceuticals logo
$14.73 +1.28 (+9.52%)
Closing price 04:00 PM Eastern
Extended Trading
$14.76 +0.04 (+0.24%)
As of 06:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Recent Syndax Pharmaceuticals SEC Filings

DateFilerForm TypeView
08/13/2025
4:52 PM
GOLDMAN SACHS GROUP INC (Filed by)
GOLDMAN SACHS GROUP INC (Filed by)
Syndax Pharmaceuticals (Subject)
Form SCHEDULE 13G/A
08/07/2025
4:30 PM
Goldan Keith A. (Reporting)
Syndax Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
07/18/2025
3:30 PM
Metzger Michael A (Reporting)
Syndax Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
07/18/2025
3:30 PM
Goldan Keith A. (Reporting)
Syndax Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
07/16/2025
2:21 PM
Metzger Michael A (Reporting)
Syndax Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/16/2025
2:29 PM
Goldan Keith A. (Reporting)
Syndax Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/10/2025
2:42 PM
Gallagher Neil (Reporting)
Syndax Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/26/2025
7:54 AM
Syndax Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/09/2025
11:34 AM
GOLDMAN SACHS GROUP INC (Filed by)
GOLDMAN SACHS GROUP INC (Filed by)
Syndax Pharmaceuticals (Subject)
Form SCHEDULE 13G/A
05/07/2025
10:25 AM
MORGAN STANLEY (Filed by)
Syndax Pharmaceuticals (Subject)
Form SCHEDULE 13G/A
03/17/2025
5:01 AM
Metzger Michael A (Reporting)
Syndax Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/07/2025
10:13 AM
Syndax Pharmaceuticals (Subject)
WELLINGTON MANAGEMENT GROUP LLP (Filed by)
Form SCHEDULE 13G/A
03/06/2025
3:10 PM
Metzger Michael A (Reporting)
Syndax Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/04/2025
8:18 AM
Syndax Pharmaceuticals (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
03/03/2025
6:02 AM
Syndax Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/03/2025
6:05 AM
Syndax Pharmaceuticals (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
02/14/2025
4:18 PM
Kynam Capital Management, LP (Filed by)
Syndax Pharmaceuticals (Subject)
Form SCHEDULE 13G/A
02/12/2025
4:13 PM
Gallagher Neil (Reporting)
Syndax Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/12/2025
4:15 PM
Metzger Michael A (Reporting)
Syndax Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/12/2025
4:16 PM
Goldan Keith A. (Reporting)
Syndax Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/12/2025
10:39 AM
GOLDMAN SACHS GROUP INC (Filed by)
GOLDMAN SACHS GROUP INC (Filed by)
Syndax Pharmaceuticals (Subject)
Form SCHEDULE 13G
02/10/2025
2:17 PM
Gallagher Neil (Reporting)
Syndax Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/10/2025
2:20 PM
Metzger Michael A (Reporting)
Syndax Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/10/2025
2:29 PM
Goldan Keith A. (Reporting)
Syndax Pharmaceuticals (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/07/2025
3:35 PM
Jarrett Jennifer (Reporting)
Syndax Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/07/2025
3:37 PM
Katkin Keith (Reporting)
Syndax Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/07/2025
3:38 PM
Meury William (Reporting)
Syndax Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/07/2025
3:39 PM
Rizo Aleksandra (Reporting)
Syndax Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/07/2025
3:41 PM
Podlesak Dennis (Reporting)
Syndax Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/07/2025
3:42 PM
Metzger Michael A (Reporting)
Syndax Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/07/2025
3:44 PM
Goldan Keith A. (Reporting)
Syndax Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/07/2025
3:45 PM
Gallagher Neil (Reporting)
Syndax Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/07/2025
3:32 PM
Legault Pierre (Reporting)
Syndax Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/05/2025
9:03 AM
MORGAN STANLEY (Filed by)
Syndax Pharmaceuticals (Subject)
Form SCHEDULE 13G
01/22/2025
4:50 PM
Point72 Asset Management, L.P. (Filed by)
Syndax Pharmaceuticals (Subject)
Form SCHEDULE 13G
12/20/2024
4:00 PM
Syndax Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/12/2024
6:05 AM
Syndax Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/08/2024
9:52 AM
Syndax Pharmaceuticals (Subject)
WELLINGTON MANAGEMENT GROUP LLP (Filed by)
Form SC 13G/A
11/05/2024
3:02 PM
Syndax Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/05/2024
3:03 PM
Syndax Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
10/18/2024
10:49 AM
STATE STREET CORP (Filed by)
Syndax Pharmaceuticals (Subject)
Form SC 13G/A
New law could create $3.7 trillion tsunami. (Ad)

During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’s Project MAFA,” and it could soon return America to a “new” gold standard. The Trump administration, Wall Street, and Silicon Valley are all pushing it forward. The President himself calls the plan “incredible.” Already, it’s helping small plays jump as high as 300%, 318%, 520%, and even 600%.

(Data available from 1/1/2016 forward)


Related Companies and Tools


This page (NASDAQ:SNDX) was last updated on 8/14/2025 by MarketBeat.com Staff
From Our Partners